Pancreatic Cancer Research

ResearcherUniversity of AucklandActive in the last 2 years

John Albert Windsor

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5995-5432; OpenAlex author ID A5029294938, A5125113432. Sources: OpenAlex.

Their work

Papers
24 (first author 1, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
66
Papers, trials and grants by year

2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers

Papers 24

  1. Factors Associated With Pancreatectomy Among Australians With Pancreatic Cancer: A Population-Based Study. Co-author DOI 10.1111/ans.70788↗
  2. Surgery for Locally Advanced Pancreatic Ductal Adenocarcinoma: Selection of Patients and Surgical Technique. Last author DOI 10.1159/000550333↗
  3. The sensitivity of decision support tools for identifying patients with pancreatic cancer: an observational study. Co-author DOI 10.3399/bjgpo.2025.0142↗
  4. When does delay in treatment impact survival from pancreatic cancer? First author DOI 10.1016/j.pan.2025.01.006↗
  5. Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australia: a cross-sectional survey study. Last author DOI 10.1007/s00520-024-08604-1↗
  6. Prescribing of pancreatic enzyme therapy for malabsorption in unresectable pancreatic cancer: Cross-sectional survey across New Zealand and Australia. Last author DOI 10.1016/j.pan.2024.10.008↗
  7. Recruitment of participants with pancreatic cancer to a mixed media study for optimal recruitment in an Australasian survey of pancreatic enzyme replacement. Last author DOI 10.1136/bmjopen-2023-076242↗
  8. The Anti-Tubercular Aminolipopeptide Trichoderin A Displays Selective Toxicity against Human Pancreatic Ductal Adenocarcinoma Cells Cultured under Glucose Star… Co-author DOI 10.3390/pharmaceutics15010287↗
  9. Patient volume and clinical outcome after pancreatic cancer resection: A contemporary systematic review and meta-analysis. Last author DOI 10.1016/j.surg.2021.11.029↗
  10. Clinically Relevant Biology of Hyaluronic Acid in the Desmoplastic Stroma of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002154↗
  11. Is Margin Status Less Prognostic After Neoadjuvant Chemoradiotherapy for Pancreatic Adenocarcinoma? Co-author DOI 10.1245/s10434-021-10885-3↗
  12. A decision support tool for the detection of pancreatic cancer in general practice: A modified Delphi consensus. Co-author DOI 10.1016/j.pan.2021.08.007↗
  13. Targeting Macrophage Migration Inhibitory Factor in Acute Pancreatitis and Pancreatic Cancer. Co-author DOI 10.3389/fphar.2021.638950↗
  14. The Impact of the Depth of Venous Invasion on Survival Following Pancreatoduodenectomy for Pancreatic Cancer: a Meta-analysis of Available Evidence. Co-author DOI 10.1007/s12029-019-00248-3↗
  15. Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis. Co-author DOI 10.3390/jcm9072132↗
  16. Biomarkers Urgently Needed to Advance Treatment Decisions for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2019.0502↗
  17. Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1111/ans.14764↗
  18. Preoperative biliary drainage in resectable pancreatic cancer: a systematic review and network meta-analysis. Last author DOI 10.1016/j.hpb.2017.12.007↗
  19. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Co-author DOI 10.1016/j.pan.2017.11.011↗
  20. Pain in pancreatic ductal adenocarcinoma: A multidisciplinary, International guideline for optimized management. Co-author DOI 10.1016/j.pan.2018.04.008↗
  21. Does revision of resection margins based on frozen section improve overall survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma? A met… Last author DOI 10.1016/j.hpb.2017.03.006↗
  22. The concept of 'borderline resectable' pancreatic cancer: limited foundations and limited future? Co-author DOI 10.21037/jgo.2016.12.06↗
  23. Borderline Resectable Pancreatic Cancer: Answering the Most Important Question First. Co-author DOI 10.1001/jamasurg.2016.1150↗
  24. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.10.013↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sanjay Pandanaboyana · 6 shared papers, 2017–2026 · strength 1.05
  2. Savio George Barreto · 5 shared papers, 2017–2026 · strength 0.98
  3. Benjamin P. T. Loveday · 3 shared papers, 2019–2026 · strength 0.67
  4. Helen J. Brown · 3 shared papers, 2023–2024 · strength 0.60
  5. Meera Ruth Agar · 3 shared papers, 2023–2024 · strength 0.60
  6. Amanda Landers · 3 shared papers, 2023–2024 · strength 0.60
  7. Rachel Ε. Neale · 3 shared papers, 2021–2026 · strength 0.56
  8. Daniel Gerald Croagh · 3 shared papers, 2021–2026 · strength 0.56
  9. Andrew J. Metz · 3 shared papers, 2021–2026 · strength 0.56
  10. Bettina Rau · 1 shared paper, 2025 · strength 0.54
  11. John Raymond Zalcberg · 2 shared papers, 2026 · strength 0.45
  12. Mary A. Waterhouse · 2 shared papers, 2026 · strength 0.45
  13. Bathiya Ratnayake · 3 shared papers, 2020–2022 · strength 0.43
  14. Anubhav Mittal · 1 shared paper, 2026 · strength 0.39
  15. Mark P. Callery · 1 shared paper, 2022 · strength 0.33
  16. Bridie S. Thompson · 2 shared papers, 2021–2026 · strength 0.32
  17. Sitwat Ali · 1 shared paper, 2026 · strength 0.24
  18. Arrisonia Doubatty · 1 shared paper, 2026 · strength 0.24
  19. Javiera Martínez-Gutiérrez · 1 shared paper, 2026 · strength 0.21
  20. Silja Schrader · 1 shared paper, 2026 · strength 0.21
  21. Jon D. Emery · 1 shared paper, 2026 · strength 0.21
  22. Iman Kavianinia · 1 shared paper, 2023 · strength 0.19
  23. Johanes K. Kasim · 1 shared paper, 2023 · strength 0.19
  24. Cristin Gregor Print · 1 shared paper, 2022 · strength 0.19
  25. Hossein Jahedi · 1 shared paper, 2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.